{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'PK Assessments', 'Added PK assessments for bortezomib and selinexor in a subset of patients', 'randomized to each arm (ie, the Vd Arm and the SVd Arm) in order to explore', 'exposure-response relationships and drug-drug interactions between bortezomib and', 'selinexor, and to evaluate any differences in PK related to age, race, sex, BMI,', 'baseline disease state, or other demographic characteristics (Modified sections:', 'Section 10.2.3.1 and Table 2; New Sections 5.1.4, 5.2.4, 11.4, and 13.6).', 'Clinical Safety Assessments', \"Clarified that BSA should be recalculated if the patient's weight fluctuates\", 'substantially from baseline (ie, >20%) during treatment (including Vd, SVd, SVdX,', 'and SdX) (Modified sections: Global).', 'Analysis Populations', 'Revised the definition of the per-protocol (PP) population from all ITT patients who', 'have received \"any amount\" to \"at least 1 dose \"of study treatment to clarify that the', 'population does not include patients who have not received study treatment', '(Modified sections: Synopsis and Section 13.3.2).', 'Efficacy Analysis', 'Added justification for the sample size calculation assumptions. This change was', 'made to address the FDA request to provide justification for the assumptions for the', 'sample size calculation (Modified sections: Sections 13.2.1 and 13.2.2).', 'Specified that an independent third party (the DSMB) will conduct and review the', 'sample size re-estimation and that an interim analysis charter will be created to', 'outline the operational procedures associated with both PFS IAs. This change was', 'made to address the FDA recommendation that the conduct/review of the sample size', 're-estimation be conducted by an independent third party (Modified section:', 'Section 13.2.3.1).', 'Clarified timing and details for the second IA (Modified section: Section 13.2.3.2).', 'Added a sensitivity analysis using the Breslow-Day test to evaluate the homogeneity', 'of odds ratios across the strata associated with the ORR endpoint and the two', 'secondary efficacy endpoint analyses which are analyzed using the Cochran-Mantel-', 'Haenszel test. This change was made to address the FDA request to include a', 'sensitivity analysis to evaluate the robustness of secondary efficacy endpoints', 'analysis results. (Modified sections: Sections 13.5.1 and 13.5.2).', 'Added sensitivity analyses for the primary efficacy endpoint and the key secondary', 'efficacy endpoints to address the FDA request to provide sensitivity analyses to', 'evaluate the robustness of efficacy results in the protocol, which includes different', 'censoring rules for the analyses of time-to-event endpoints. The sensitivity analyses,', 'based on the guidance \"Clinical Trial Endpoints for the Approval of Cancer Drugs', 'and Biologics\" will consider the events in which patients have taken other anticancer', 'therapy, missed assessments, or been lost-to-follow-up (Modified sections:', 'Sections 13.5.1.1, 13.5.1.2, and 13.5.2).', 'Confidential', 'Page 146', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Clarified that all changes in MM disease assessments will be based on baseline MM', 'disease assessments from C1D1 of study treatment (Modified sections:', 'Sections 5.2.1 and 13.5.1.2).', 'Added a method for testing the proportional hazard assumption associated with the', 'analyses of the primary and key secondary time-to-event endpoints. This change was', 'made to address the FDA request to include a method for testing the assumption of', 'the proportional hazard model and evaluate the impact of the varying hazard ratios on', 'the conclusion (Modified section: Section 13.5.1.1).', 'CCI', 'Safety Analysis', \"Revised the correction for QTc from Bazett's to Fridericia's to address the FDA\", \"request to use the Fridericia's correction for QTc correction instead of Bazett's.\", \"Fridericia's is more effective for rejection of false positive results (Guidance for\", 'Industry entitled E14 Clinical Evaluation of QT/QTc Interval Prolongation)', '(Modified sections: Sections 11.5.1.3, 13.7.5, and 15).', 'Safety Definitions, Recording and Reporting', 'Revised start time for recording of AEs from \"from the first dose of study treatment', 'on C1D1 \"to \"after the patient has provided informed consent\" to ensure compliance', 'with regulations (Modified sections: Section 12.1.2 and Table 2).', 'Minor wording changes to improve clarity related to reporting of SAEs and', 'pregnancies (Modified sections: Sections 12.2, 12.2.2, 12.2.3, and 12.3.1).', 'Added the following regulatory definition for serious hospitalizations: \"A', \"hospitalization meeting the regulatory definition for 'serious' is any inpatient hospital\", \"admission that includes a minimum of an overnight stay in a health care facility.'\", '(Modified section: Section 12.2).', 'Expanded section related to handling overdoses to cover, abuse, misuse, medication', 'errors, and occupational exposure and created related subsections. Also removed the', 'paragraph detailing supportive measures for patients who develop liver function test', 'abnormalities in the event of an overdose and added detailed reporting requirements', '(Modified section: Section 12.3.2).', 'Moved text related to supportive measures for possible hepatic GSH depletion in the', 'case of extreme overdose to the supportive care section because it is not relevant to', 'the safety section (Modified section: Section 12.3.2; New section: 10.3.5).', 'Confidential', 'Page 147', 'Version 4.0']\n\n###\n\n", "completion": "END"}